Problem-solving articles |
|
Shandala M.G.
Disinfectology as an important component of the antimicrobial defense system
|
4-7 |
Original investigations |
|
Arefieva L.I., Gorskaya E.M., Savostianova O.A., Spirina T.S., Romashkina L.Yu., Gabrielyan N.I.
Postoperative bacteremias in cardiac surgical patients
|
8-12 |
|
Pudova E.A., Chekanova T.A., Markelov M.L., Dedkov V.G., Kirdyashkina N.P., Karaseva I.P., Sazhin A.I., Zatsepin T.S., Utkin D.V., Osina N.A., Shcherbakova S.A., Shipulin G.A.
Development and testing of a DNA microarray for identification of particularly dangerous infectious pathogens
|
13-19 |
|
Lebedeva T.M., Egorova N.Yu., Koltunov I.E., Karazhas N.V., Rybalkina T.N., Kalugina M.Yu., Uchaykin V.F.
Herpesviridae and long-term subfebrility
|
20-24 |
|
Kisteneva L.B., Cheshik S.G., Kolobukhina L.V., Okolysheva N.V.
Cytomegalovirus infection in women with a bad obstetric history (pregravid preparation for pregnancy)
|
25-29 |
|
Semenova N.Yu., Chebotareva T.V., Bogdanova L.I., Demidov V.I.
The clinical and morphological features of HIV-associated tuberculosis
|
30-34 |
Reviews and lectures |
|
Vikulov G.Kh.
Human herpesvirus infections in the new millennium: сlassification, epidemiology, and sociomedical importance
|
35-40 |
|
Raduto O.I.
Clinical and economic aspects of parenteral hepatitis C
|
41-45 |
|
Ignatova T.M.
Use of telaprevir in real clinical practice
|
46-52 |
Discussion |
|
Fokina E.G.
Round table «Adaptive Mechanisms in Diphtheria and Erysipelas»
|
53-57 |
Exchange of experience |
|
Mikhaylova E.V., Chudakova T.K., Danilov A.N.
The clinical features of acute respiratory viral infections and the improvement of therapy in a group of frequently ill children
|
58-62 |
|
Khasanova G.R.
Lipodystrophy syndrome in patients with HIV infection
|
63-69 |
|
Moskvicheva M.G., Radzikhovskaya M.V.
Experience with the HIV protease inhibitor fosamprenavir in first-line antiretroviral therapy regimens in the Chelyabinsk Region
|
70-75 |
Current events |
|
Sixth Annual All-Russian Congress on Infectious Diseases
|
76-78 |
|
Possible use of the new antiretroviral drug a fixed-dose combination of TDF/RPV/FTC registered as Evipler for the treatment of HIV-1 infection (Record of the meeting)
|
79-80 |
Русский
